Tal Gilboa

Abstract:
The quantification and characterization of aggregated α-synuclein in clinical samples offer immense potential toward diagnosing, treating, and better understanding neurodegenerative synucleinopathies. Here, we developed digital seed amplification assays to detect single α-synuclein aggregates by partitioning the reaction into microcompartments. Using brain tissue and cerebrospinal fluid samples collected from patients with Parkinson’s Disease and multiple system atrophy, we demonstrated that the assay can detect endogenous pathological α-synuclein aggregates. 

We congratulate Tal on having her work featured on Harvard Medical School’s website.